govinfo:USCOURTS-njd-1_08-cv-00008-13

NOT FOR PUBLICATION 
IN THE UNITED STATES DISTRICT COURT 
FOR THE DISTRICT OF NEW JERSEY 
CAMDEN VICINAGE 
IN RE: FOSAMAX® 
(ALENDRONATE SODIUM): 
PRODUCTS LIABILITY LITIGATION 
(NO. II) 
HONORABLE J(AREN M. WILLIAMS 
MDL No.2243 
Master Docket No. 1:08-cv-00008-KMW­
MJS 
Filed Electronically 
MEMORANDUM OPINION 
AND ORDER
THIS MATTER comes before the Court by way of Defendants Genentech, Inc.; 
GlaxoSmithKline LLC; Hoffman-La Roche Inc.; and Roche Laboratories Inc. (collectively, 
"Boniva Defendants") Motion to Dismiss (Dkt. No. 4907) the complaints of the Plaintiffs 
identified in Exhibit A t ("Exhibit A' Plaintiffs") (see Dkt. No. 4915-1) without prejudice pursuant 
to Fed. R. Civ. P. 41 (b) for failure to comply with Case Management Order 22 ("CMO 22"). (Dkt. 
No. 4901.) The Court has considered the parties' submissions without oral argument pursuant to 
L.Civ.R. 78.l (b ).
WHEREAS, on March 12, 2026, the Honorable Matthew J. Skahill, U.S.M.J. entered 
CMO 22 (Dkt. No. 4901) requiring all plaintiffs in this proceeding, including those listed in Exhibit 
A, their representatives, or anticipated representatives to complete and return the applicable 
certification attached to CMO 22 no later than 45 days after the entry thereof-that date being 
April 27, 2026, (Dkt. No. 4901 at 3, ,r 5; see Christian Deel., Dkt. No. 4907-1 at 2, ,r 3); and 
1 "Exhibit A Plaintiffs" refers to the Plaintiffs listed in the Third Amended Exhibit A attached to the letter submitled 
by counsel Boniva Defendanls, Randall L. Christian Esq., dated May 26, 2026 (Dkt. No. 4915). A copy of the Exhibit 
A Plaintiffs (Dkt. No. 4915-1) is attached to this Memorandum Order and Opinion as "Exhibit A." PageID:
<pageID> PageID:
<pageID> PageID:
<pageID> PageID:
<pageID>

Passage view · GavelSight